{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T01:59:20Z","timestamp":1792202360703,"version":"4.4.0"},"reference-count":94,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T00:00:00Z","timestamp":1653523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>Heart failure (HF) remains the leading cause of death, morbidity, and medical expenses worldwide. Treatments for HF with reduced ejection fraction have progressed in recent years; however, acute decompensated heart failure remains difficult to treat. The transient receptor potential (TRP) channel family plays roles in various cardiovascular diseases, responding to neurohormonal and mechanical load stimulation. Thus, TRP channels are promising targets for drug discovery, and many studies have evaluated the roles of TRP channels expressed on pain neurons. The natriuretic peptide (NP) family of proteins regulates blood volume, natriuresis, and vasodilation and can antagonize the renin-angiotensin-aldosterone system and participate in the pathogenesis of major cardiovascular diseases, such as HF, coronary atherosclerotic heart disease, and left ventricular hypertrophy. NPs are degraded by neprilysin, and the blood level of NPs has predictive value in the diagnosis and prognostic stratification of HF. In this review, we discuss the relationships between typical TRP family channels (e.g., transient receptor potential cation channel subfamily V member 1 andTRPV1, transient receptor potential cation channel subfamily C member 6) and the NP system (e.g., atrial NP, B-type NP, and C-type NP) and their respective roles in HF. We also discuss novel drugs introduced for the treatment of HF.<\/jats:p>","DOI":"10.3389\/fcvm.2022.904881","type":"journal-article","created":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T11:27:40Z","timestamp":1654255660000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Transient Receptor Potential Channels, Natriuretic Peptides, and Angiotensin Receptor-Neprilysin Inhibitors in Patients With Heart Failure"],"prefix":"10.3389","volume":"9","author":[{"given":"Kun","family":"Ding","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Gui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lifang","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,26]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/35077544","article-title":"The TRP ion channel family.","volume":"2","author":"Clapham","year":"2001","journal-title":"Nat Rev Neurosci."},{"key":"B2","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/s0092-8674(02)00670-0","article-title":"The TRP channels, a remarkably functional family.","volume":"108","author":"Montell","year":"2002","journal-title":"Cell."},{"key":"B3","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.pharmthera.2008.03.008","article-title":"TRP channel and cardiovascular disease.","volume":"118","author":"Watanabe","year":"2008","journal-title":"Pharmacol Ther."},{"key":"B4","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/0024-3205(81)90370-2","article-title":"A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats.","volume":"28","author":"de Bold","year":"1981","journal-title":"Life Sci."},{"key":"B5","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/332078a0","article-title":"A new natriuretic peptide in porcine brain.","volume":"332","author":"Sudoh","year":"1988","journal-title":"Nature."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/0196-9781(92)90065-b","article-title":"C-type natriuretic peptide immunoreactivity in human breast vascular endothelial cells.","volume":"13","author":"Heublein","year":"1992","journal-title":"Peptides."},{"key":"B7","doi-asserted-by":"publisher","first-page":"F464","DOI":"10.1152\/ajprenal.00372.2001","article-title":"CNP production in the kidney and effects of protein intake restriction in nephrotic syndrome.","volume":"283","author":"Cataliotti","year":"2002","journal-title":"Am J Physiol Renal Physiol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1172\/JCI115146","article-title":"Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide.","volume":"87","author":"Mukoyama","year":"1991","journal-title":"J Clin Invest."},{"key":"B9","doi-asserted-by":"publisher","first-page":"R1093","DOI":"10.1152\/ajpregu.00682.2004","article-title":"Equimolar doses of atrial and brain natriuretic peptides and urodilatin have differential renal actions in overt experimental heart failure.","volume":"288","author":"Chen","year":"2005","journal-title":"Am J Physiol Regul Integr Comp Physiol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1161\/01.res.0000046234.73401.70","article-title":"Brain natriuretic peptide is produced in cardiac fibroblasts and induces matrix metalloproteinases.","volume":"91","author":"Tsuruda","year":"2002","journal-title":"Circ Res."},{"key":"B11","first-page":"S22","article-title":"C-type natriuretic peptide: the endothelial component of the natriuretic peptide system.","volume":"32","author":"Chen","year":"1998","journal-title":"J Cardiovasc Pharmacol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"R373","DOI":"10.1152\/ajpregu.1996.271.2.R373","article-title":"Clearance receptors and endopeptidase 24.11: equal role in natriuretic peptide metabolism in conscious sheep.","volume":"271","author":"Charles","year":"1996","journal-title":"Am J Physiol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1007\/s00395-004-0460-0","article-title":"Molecular physiology of natriuretic peptide signalling.","volume":"99","author":"Kuhn","year":"2004","journal-title":"Basic Res Cardiol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.peptides.2004.09.023","article-title":"Natriuretic peptide receptor-C signaling and regulation.","volume":"26","author":"Anand-Srivastava","year":"2005","journal-title":"Peptides."},{"key":"B15","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/j.bbrc.2008.01.017","article-title":"cGMP rescues mitochondrial dysfunction induced by glucose and insulin in myocytes.","volume":"367","author":"Mitsuishi","year":"2008","journal-title":"Biochem Biophys Res Commun."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2880","DOI":"10.2337\/db09-0393","article-title":"Natriuretic peptides\/cGMP\/cGMP-dependent protein kinase cascades promote muscle mitochondrial bio-genesis and prevent obesity.","volume":"58","author":"Miyashita","year":"2009","journal-title":"Diabetes."},{"key":"B17","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/sj.ijo.0803724","article-title":"Angiotensin II stimulates NEP inhibition in CV disease893 and atrial natriuretic peptide inhibits human visceral adipocyte growth.","volume":"32","author":"Sarzani","year":"2008","journal-title":"Int J Obes."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1172\/JCI59701","article-title":"Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat thermogenic program in mouse and human adipocytes.","volume":"122","author":"Bordicchia","year":"2012","journal-title":"J Clin Invest."},{"key":"B19","doi-asserted-by":"publisher","first-page":"475","DOI":"10.3181\/0708-RM-216","article-title":"B-type natriuretic peptide decreases gastric emptying and absorption.","volume":"233","author":"Addisu","year":"2008","journal-title":"Exp Biol Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1093\/hmg\/ddm084","article-title":"Association between the T-381C polymorphism of the brain natriuretic peptide gene and risk of type 2 diabetes in human populations.","volume":"16","author":"Meirhaeghe","year":"2007","journal-title":"Hum Mol Genet."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1093\/hmg\/ddp169","article-title":"The T-381C SNP in BNP gene may be modestly associated with type 2 diabetes: an updated meta-analysis in 49 279 subjects.","volume":"18","author":"Choquet","year":"2009","journal-title":"Hum Mol Genet."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1016\/j.jacc.2009.02.038","article-title":"Natriuretic peptides enhance the production of adiponectin in human adipocytes and in patients with chronic heart failure.","volume":"53","author":"Tsukamoto","year":"2009","journal-title":"J Am Coll Cardiol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.2337\/db08-0649","article-title":"Atrial natriuretic peptide induces postprandial lipid oxidation in humans.","volume":"57","author":"Birkenfeld","year":"2008","journal-title":"Diabetes."},{"key":"B24","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1038\/ng.328","article-title":"Association of common variants in NPPA and NPPB with circulating natriuretic peptides and blood pressure.","volume":"41","author":"Newton-Cheh","year":"2009","journal-title":"Nat Genet."},{"key":"B25","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.jacc.2011.05.011","article-title":"A genetic variant of the atrial natriuretic peptide gene is associated with cardiometabolic protection in the general community.","volume":"58","author":"Cannone","year":"2011","journal-title":"J Am Coll Cardiol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1210\/jc.2011-2425","article-title":"Low plasma level of atrial natriuretic peptide predicts development of diabetes: the prospective Malmo Diet and Cancer study.","volume":"97","author":"Magnusson","year":"2012","journal-title":"J Clin Endocrinol Metab."},{"key":"B27","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1161\/01.CIR.0000112582.16683.EA","article-title":"Impact of obesity on plasma natriuretic peptide levels.","volume":"109","author":"Wang","year":"2004","journal-title":"Circulation."},{"key":"B28","doi-asserted-by":"publisher","first-page":"H1529","DOI":"10.1152\/ajpheart.00107.2006","article-title":"Lack of activation of molecular forms of the BNP system in human grade 1 hypertension and relationship to cardiac hypertrophy.","volume":"291","author":"Belluardo","year":"2006","journal-title":"Am J Physiol Heart Circ Physiol."},{"key":"B29","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.jacc.2011.01.005","article-title":"Human hypertension is characterized by a lack of activation of the anti-hypertensive cardiac hormones ANP and BNP.","volume":"57","author":"Macheret","year":"2011","journal-title":"J Am Coll Cardiol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1001\/jama.287.12.1531","article-title":"Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial.","volume":"287","year":"2002","journal-title":"J Am Med Assoc."},{"key":"B31","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1056\/NEJM200007273430403","article-title":"Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group.","volume":"343","author":"Colucci","year":"2000","journal-title":"N Engl J Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1517\/13543784.10.5.935","article-title":"An update on nesiritide for treatment of decompensated heart failure.","volume":"10","author":"Hobbs","year":"2001","journal-title":"Expert Opin Investig Drugs."},{"key":"B33","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1517\/13543784.13.6.643","article-title":"Recent advances in natriuretic peptides in congestive heart failure.","volume":"13","author":"Boerrigter","year":"2004","journal-title":"Expert Opin Investig Drugs."},{"key":"B34","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1023\/A:1014260204524","article-title":"Biochemistry and physiology of the natriuretic peptide receptor guanylyl cyclases.","volume":"230","author":"Tremblay","year":"2002","journal-title":"Mol Cell Biochem."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1172\/JCI18389","article-title":"A friend within the heart: natriuretic peptide receptor signaling.","volume":"111","author":"Molkentin","year":"2003","journal-title":"J Clin Invest."},{"key":"B36","doi-asserted-by":"publisher","first-page":"211","DOI":"10.4196\/kjpp.2012.16.3.211","article-title":"Activation of the cGMP\/protein kinase G pathway by nitric oxide can decrease TRPV1 activity in cultured rat dorsal root ganglion neurons.","volume":"16","author":"Jin","year":"2012","journal-title":"Korean J Physiol Pharmacol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"12480","DOI":"10.1073\/pnas.2032100100","article-title":"Protein kinase C phosphorylation sensitizes but does not activate the capsaicin receptor transient receptor potential vanilloid 1 (TRPV1).","volume":"100","author":"Bhave","year":"2003","journal-title":"Proc Natl Acad Sci USA."},{"key":"B38","doi-asserted-by":"publisher","first-page":"13424","DOI":"10.1074\/jbc.M410917200","article-title":"Regulation of Ca2+-dependent desensitization in the vanilloid receptor TRPV1 by cal- cineurin and cAMP-dependent protein kinase.","volume":"280","author":"Mohapatra","year":"2005","journal-title":"J Biol Chem."},{"key":"B39","doi-asserted-by":"publisher","first-page":"11363","DOI":"10.1073\/pnas.162100799","article-title":"Inhibition of calcineurin-NFAT hypertrophy signaling by cGMP-dependent protein kinase type I in cardiac myocytes.","volume":"99","author":"Fiedler","year":"2002","journal-title":"Proc Natl Acad Sci USA."},{"key":"B40","doi-asserted-by":"publisher","first-page":"5305","DOI":"10.1038\/sj.emboj.7601417","article-title":"TRPC3 and TRPC6 are essential for angiotensin II-induced cardiac hypertrophy.","volume":"25","author":"Onohara","year":"2006","journal-title":"EMBO J."},{"key":"B41","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1139\/y01-039","article-title":"Pathophysiological significance and clinical application of ANP and BNP in patients with heart failure.","volume":"79","author":"Yoshimura","year":"2001","journal-title":"Can J Physiol Pharmacol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1161\/CIRCRESAHA.109.208314","article-title":"Inhibition of TRPC6 channel activity contributes to the antihypertrophic effects of natriuretic peptides-guanylyl cyclase-A signaling in the heart.","volume":"106","author":"Kinoshita","year":"2010","journal-title":"Circ Res."},{"key":"B43","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/35093019","article-title":"Molecular mechanisms of nociception.","volume":"413","author":"Julius","year":"2001","journal-title":"Nature."},{"key":"B44","first-page":"833","article-title":"The P2X3 subunit: a molecular target in pain therapeutics.","volume":"4","author":"North","year":"2003","journal-title":"Curr Opin Investig Drugs."},{"key":"B45","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1126\/science.288.5464.306","article-title":"Impaired nociception and pain sensation in mice lacking the capsaicin receptor.","volume":"288","author":"Caterina","year":"2000","journal-title":"Science."},{"key":"B46","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/35012076","article-title":"Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia.","volume":"405","author":"Davis","year":"2000","journal-title":"Nature."},{"key":"B47","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1124\/jpet.104.079855","article-title":"AMG9810 [(E)-3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo[b][1,4] dioxin-6-yl)acrylamide], a novel vanilloid receptor 1 (TRPV1) antagonist with antihyperalgesic properties.","volume":"313","author":"Gavva","year":"2005","journal-title":"J Pharmacol Exp Ther."},{"key":"B48","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.lfs.2012.08.010","article-title":"TRP channels and analgesia.","volume":"92","author":"Premkumar","year":"2013","journal-title":"Life Sci."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1177\/0022034510377094","article-title":"Substance Psensitizes P2X3 in nociceptive trigeminal neurons.","volume":"89","author":"Park","year":"2010","journal-title":"J Dent Res."},{"key":"B50","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s12035-008-8020-5","article-title":"Molecular mechanisms of sensitization of pain-transducing P2X3 receptors by the migraine mediators CGRP and NGF.","volume":"37","author":"Giniatullin","year":"2008","journal-title":"Mol Neurobiol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"18743","DOI":"10.1074\/jbc.M800296200","article-title":"Mechanisms mediating the enhanced gene transcription of P2X3 receptor by calcitonin gene- related peptide in trigeminal sensory neurons.","volume":"283","author":"Simonetti","year":"2008","journal-title":"J Biol Chem."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/j.neuropharm.2008.08.037","article-title":"Phosphorylation of TRPV1 by neurokinin-1 receptor agonist exaggerates the capsaicin-mediated substance P release from cultured rat dorsal root ganglion neurons.","volume":"55","author":"Tang","year":"2008","journal-title":"Neuropharmacology."},{"key":"B53","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/0091-3057(92)90657-2","article-title":"Effects of atrial natriuretic peptide on acute and chronic effects of morphine.","volume":"43","author":"Azarov","year":"1992","journal-title":"Pharmacol Biochem Behav."},{"key":"B54","doi-asserted-by":"publisher","first-page":"11184","DOI":"10.1523\/JNEUROSCI.6159-10.2011","article-title":"CNGA3: a target of spinal nitric oxide\/cGMP signaling and modulator of inflammatory pain hypersensitivity.","volume":"31","author":"Heine","year":"2011","journal-title":"J Neurosci."},{"key":"B55","doi-asserted-by":"publisher","first-page":"8568","DOI":"10.1523\/JNEUROSCI.2128-08.2008","article-title":"cGMP produced by NO-sensitive guanylyl cyclase essentially contributes to inflammatory and neuropathic pain by using targets different from cGMP-dependent protein kinase I.","volume":"28","author":"Schmidtko","year":"2008","journal-title":"J Neurosci."},{"key":"B56","doi-asserted-by":"publisher","first-page":"11942","DOI":"10.1523\/JNEUROSCI.1330-12.2012","article-title":"The C-type natriuretic peptide induces thermal hyperalgesia through a noncanonical G\u03b2\u03b3-dependent modulation of TRPV1 channel.","volume":"32","author":"Loo","year":"2012","journal-title":"J Neurosci."},{"key":"B57","doi-asserted-by":"publisher","first-page":"10927","DOI":"10.1523\/JNEUROSCI.0657-10.2010","article-title":"Inhibitionof inflammatory pain by activating B-type natriuretic peptide signal pathway in nociceptive sensory neurons.","volume":"30","author":"Zhang","year":"2010","journal-title":"J Neurosci."},{"key":"B58","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1023\/A:1014257621362","article-title":"Natriuretic peptide receptor: structure and signaling.","volume":"230","author":"Misono","year":"2002","journal-title":"Mol Cell Biochem."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1152\/physrev.00015.2005","article-title":"Function of cGMP-dependent protein kinases as revealed by gene deletion.","volume":"86","author":"Hofmann","year":"2006","journal-title":"Physiol Rev."},{"key":"B60","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/978-3-540-68964-5_15","article-title":"Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic applications.","volume":"191","author":"Potter","year":"2009","journal-title":"Handb Exp Pharmacol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/j.peptides.2005.03.055","article-title":"Natriuretic peptides and their receptors.","volume":"26","author":"Pandey","year":"2005","journal-title":"Peptides."},{"key":"B62","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1210\/er.2005-0014","article-title":"Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions.","volume":"27","author":"Potter","year":"2006","journal-title":"Endocr Rev."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1523\/JNEUROSCI.5037-07.2008","article-title":"Cysteine-rich protein 2, a novel down-stream effector of cGMP\/cGMP-dependent protein kinase I-mediated persistent inflammatory pain.","volume":"28","author":"Schmidtko","year":"2008","journal-title":"J Neurosci."},{"key":"B64","doi-asserted-by":"crossref","first-page":"11184","DOI":"10.1523\/JNEUROSCI.6159-10.2011","article-title":"CNGA3: a target of spinal nitric oxide\/cGMP signaling and modulator of inflammatory pain hypersensitivity.","volume":"31","author":"Heine","year":"2011","journal-title":"J Neurosci."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1126\/science.1062246","article-title":"Allosteric activation of a spring-loaded natriuretic peptide receptor dimer by hormone.","volume":"293","author":"He","year":"2001","journal-title":"Science."},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1186\/1744-8069-5-17","article-title":"High concentrations of morphine sensitize and activate mouse dorsal root ganglia via TRPV1 and TRPA1 receptors.","volume":"5","author":"Forster","year":"2009","journal-title":"Mol Pain."},{"key":"B67","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/s0898-6568(96)00174-x","article-title":"G proteins and opioid receptor-mediated signalling.","volume":"9","author":"Standifer","year":"1997","journal-title":"Cell Signal."},{"key":"B68","first-page":"69","article-title":"Opioid receptors on peripheral sensory neurons.","volume":"521","author":"Stein","year":"2003","journal-title":"Adv Exp Med Biol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"967","DOI":"10.2174\/0929867033457656","article-title":"Ca(2+)-handling proteins and heart failure:novel molecular targets?.","volume":"10","author":"Prestle","year":"2003","journal-title":"Curr Med Chem."},{"key":"B70","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1196\/annals.1380.015","article-title":"Regulation of Ca2+and Na+in normal and failing cardiac myocytes.","volume":"1080","author":"Bers","year":"2006","journal-title":"Ann N Y Acad Sci."},{"key":"B71","doi-asserted-by":"publisher","first-page":"16683","DOI":"10.1073\/pnas.0407537101","article-title":"Sarco (endo)plasmic reticulum Ca2+ATPase (SERCA) gene silencing and remodeling of the Ca2+signaling mechanism in cardiac myocytes.","volume":"101","author":"Seth","year":"2004","journal-title":"Proc Natl Acad Sci USA."},{"key":"B72","doi-asserted-by":"publisher","first-page":"3114","DOI":"10.1172\/JCI27702","article-title":"TRPC6 fulfills a calcineurin signaling circuit during pathologic cardiac remodeling.","volume":"116","author":"Kuwahara","year":"2006","journal-title":"J Clin Invest."},{"key":"B73","doi-asserted-by":"publisher","first-page":"33487","DOI":"10.1074\/jbc.M605536200","article-title":"Canonical transient receptor potential channels promote cardiomyocyte hypertrophy through activation of calcineurin signaling.","volume":"281","author":"Bush","year":"2006","journal-title":"J Biol Chem."},{"key":"B74","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/s1471-4914(03)00025-x","article-title":"Apoptosis in heart: basic mechanisms and implications in cardiovascular diseases.","volume":"9","author":"Kang","year":"2003","journal-title":"Trends Mol Med."},{"key":"B75","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1038\/sj.cdd.4401813","article-title":"Activation of the transient receptor potential M2 channel and poly(ADP-ribose) polymerase is involved in oxidative stress-induced cardiomyocyte death.","volume":"13","author":"Yang","year":"2006","journal-title":"Cell Death Differ."},{"key":"B76","doi-asserted-by":"publisher","first-page":"L1267","DOI":"10.1152\/ajplung.00515.2005","article-title":"Functional expression of transient receptor potential melastatin- and vanilloid-related channels in pulmonary arterial and aortic smooth muscle.","volume":"290","author":"Yang","year":"2006","journal-title":"Am J Physiol Lung Cell Mol Physiol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s11010-006-9261-0","article-title":"Transient receptor potential (TRP) protein 7 acts as a G protein-activated Ca2+ channel mediating angiotensin II-induced myocardial apoptosis.","volume":"294","author":"Satoh","year":"2007","journal-title":"Mol Cell Biochem."},{"key":"B78","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1056\/nejm199908193410806","article-title":"Hormones and hemodynamics in heart failure.","volume":"341","author":"Schrier","year":"1999","journal-title":"N Engl J Med."},{"key":"B79","doi-asserted-by":"publisher","first-page":"3404","DOI":"10.1016\/j.ijcard.2013.04.164","article-title":"Comparison of the diagnostic and prognostic values of B-type and atrial-type natriuretic peptides in acute heart failure.","volume":"168","author":"Seronde","year":"2013","journal-title":"Intern J Cardiol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1016\/j.ijcard.2013.01.228","article-title":"Incremental value of biomarkers to clinical variables for mortality prediction in acutely decompensated heart failure: the Multinational Observational Cohort on Acute Heart Failure (MOCA) study.","volume":"168","author":"Lassus","year":"2013","journal-title":"Int J Cardiol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.hfc.2009.04.002","article-title":"Natriuretic peptides in the diagnosis and management of chronic heart failure.","volume":"5","author":"Boerrigter","year":"2009","journal-title":"Heart Fail Clin."},{"key":"B82","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1002\/clc.20813","article-title":"Prediction of long-term survival in chronic heart failure by multiple biomarker assessment: a 15-year prospective follow-up study.","volume":"33","author":"Volpe","year":"2010","journal-title":"Clin Cardiol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1016\/j.jacc.2012.12.044","article-title":"B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction.","volume":"61","author":"van Veldhuisen","year":"2013","journal-title":"J Am Coll Cardiol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1001\/jama.2013.7588","article-title":"Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial.","volume":"310","author":"Ledwidge","year":"2013","journal-title":"JAMA."},{"key":"B85","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1097\/HPC.0b013e3181c4a0c6","article-title":"Natriuretic peptide-guided management of acutely destabilized heart failure. Rationale and treatment algorithm.","volume":"8","author":"Bhardwaj","year":"2009","journal-title":"Crit Pathw Cardiol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/clpt.2012.187","article-title":"The role of natriuretic peptides as biomarkers for guiding the management of chronic heart failure.","volume":"93","author":"Motiwala","year":"2013","journal-title":"Clin Pharm Ther."},{"key":"B87","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1161\/CIRCULATIONAHA.109.192064","article-title":"2009 Focused update: ACCF\/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the international society for heart and lung transplantation.","volume":"119","author":"Jessup","year":"2009","journal-title":"Circulation."},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0058287","article-title":"Natriuretic peptide-guided therapy in chronic heart failure: a meta-analysis of 2,686 patients in 12 randomized trials.","volume":"8","author":"Savarese","year":"2013","journal-title":"PLoS One."},{"key":"B89","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure.","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med."},{"key":"B90","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1093\/eurjhf\/hft052","article-title":"Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF).","volume":"15","author":"McMurray","year":"2013","journal-title":"Eur J Heart Fail."},{"key":"B91","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1002\/ejhf.115","article-title":"Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF).","volume":"16","author":"McMurray","year":"2014","journal-title":"Eur J Heart Fail."},{"key":"B92","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.amjhyper.2003.09.014","article-title":"Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial.","volume":"17","author":"Kostis","year":"2004","journal-title":"Am J Hypertens."},{"key":"B93","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1161\/circulationaha.115.018622","article-title":"Combined angiotensin receptor antagonism and neprilysin inhibition.","volume":"133","author":"Scott","year":"2016","journal-title":"Circulation."},{"key":"B94","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction.","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.904881\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T11:27:49Z","timestamp":1654255669000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.904881\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,26]]},"references-count":94,"alternative-id":["10.3389\/fcvm.2022.904881"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2022.904881","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,26]]},"article-number":"904881"}}